Abeona Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

New Accounting Standards Implemented (Details 1) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenues
Revenue from Contract with Customer, Including Assessed Tax	$ 819,000		$ 217,000	$ 3,417,000	$ 403,000
Total revenues BS	819,000			3,417,000
Expenses
Loss from operations	(12,014,000)		(8,440,000)	(20,630,000)	(13,724,000)
Net loss	$ 11,700,000	$ 8,463,000	$ 8,279,000	$ 20,163,000	$ 13,526,000
Basic and diluted loss per common share	$ (0.25)		$ (0.21)	$ (0.43)	$ (0.34)
License [Member]
Revenues
Revenue from Contract with Customer, Including Assessed Tax	$ 0		$ 150,000	$ 0	$ 301,000
As Reported Under ASC 605
Revenues
Total revenues BS	969,000			3,718,000
Expenses
Loss from operations	(11,864,000)			(20,329,000)
Net loss	(11,550,000)			(19,862,000)
As Reported Under ASC 605 \| License [Member]
Revenues
Revenue from Contract with Customer, Including Assessed Tax	150,000			301,000
Adjustments Due to ASC 606
Revenues
Total revenues BS	(150,000)			(301,000)
Expenses
Loss from operations	(150,000)			(301,000)
Net loss	(150,000)			(301,000)
Adjustments Due to ASC 606 \| License [Member]
Revenues
Revenue from Contract with Customer, Including Assessed Tax	$ (150,000)			$ (301,000)